Omnicell (NASDAQ:OMCL) Downgraded to “Hold” Rating by StockNews.com

StockNews.com cut shares of Omnicell (NASDAQ:OMCL) from a buy rating to a hold rating in a research note published on Monday.

Several other equities research analysts have also recently issued reports on OMCL. JPMorgan Chase & Co. lowered their price objective on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Wells Fargo & Company reduced their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Bank of America dropped their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Finally, Benchmark restated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Omnicell currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Trading Down 0.1 %

OMCL opened at $34.45 on Monday. Omnicell has a one year low of $25.12 and a one year high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 127.60, a P/E/G ratio of 7.53 and a beta of 0.85. The stock’s 50 day moving average price is $39.30 and its 200-day moving average price is $42.70.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, equities analysts forecast that Omnicell will post 1.09 EPS for the current year.

Institutional Trading of Omnicell

Several hedge funds and other institutional investors have recently bought and sold shares of OMCL. Smartleaf Asset Management LLC lifted its stake in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after purchasing an additional 273 shares during the last quarter. Summit Investment Advisors Inc. raised its holdings in Omnicell by 6.9% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock worth $213,000 after purchasing an additional 307 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after buying an additional 315 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares in the last quarter. Finally, Redmond Asset Management LLC boosted its holdings in shares of Omnicell by 0.3% in the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after buying an additional 371 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.